铂类时代睾丸生殖细胞癌治疗后的实体瘤风险
该多中心队列纳入5848例1976至2007年间50岁前接受治疗的睾丸癌1年生存者,中位随访14.1年,实体瘤标准化发病比为1.8。铂类化疗与实体瘤风险升高相关,尤其胃肠道肿瘤,且存在剂量效应;放疗与膈下实体瘤风险随剂量增加。
要点
- 睾丸癌幸存者实体瘤风险为一般人群1.8倍,25年累积发生率10.3%。
- 铂类化疗与实体瘤风险升高相关(HR 2.40),尤其结直肠和非结直肠胃肠道肿瘤。
- 铂类剂量每增加100 mg/m2,胃肠道实体瘤风险增加53%;放疗剂量每Gy膈下实体瘤风险增加8%。
核心结论
- 放疗和含铂化疗与实体瘤风险升高相关,尤其是胃肠道实体瘤。
研究设计与样本
- 多中心队列研究,纳入5848例1976至2007年间50岁前接受治疗的睾丸癌1年生存者。
- 采用病例-队列设计的多变量回归评估治疗特异性风险。
主要发现
- 中位随访14.1年,观察到350例实体瘤,标准化发病比1.8(95%CI 1.6-2.0)。
- 精原细胞瘤和非精原细胞瘤患者实体瘤风险均升高,标准化发病比分别为1.52和2.21。
- 非精原细胞瘤患者甲状腺、肺、胃、胰腺、结肠、膀胱肿瘤及黑色素瘤和软组织肉瘤风险升高;精原细胞瘤患者小肠、胰腺和膀胱肿瘤风险升高。
- 25年实体瘤累积发生率为10.3%(95%CI 9.0%-11.6%)。
- 铂类化疗与实体瘤风险升高相关(HR 2.40;95%CI 1.58-3.62),与结直肠实体瘤(HR 3.85;95%CI 1.67-8.92)和非结直肠胃肠道实体瘤(HR 5.00;95%CI 2.28-10.95)风险升高相关。
关键数值与推荐
- 与手术相比,铂类400-499 mg/m2和≥500 mg/m2的实体瘤风险HR分别为2.43(95%CI 1.40-4.23)和2.42(95%CI 1.50-3.90),较低剂量风险未显著升高(HR 1.75;95%CI 0.90-3.43)。
- 含铂化疗每100 mg/m2,胃肠道实体瘤HR增加53%(95%CI 26%-80%)。
- 放疗剂量每Gy,膈下实体瘤HR增加8%(95%CI 6%-9%;P < .001)。
临床怎么用
- 对接受过铂类化疗或放疗的睾丸癌幸存者,应关注实体瘤尤其是胃肠道肿瘤的长期监测。
- 铂类累积剂量和放疗剂量与实体瘤风险相关,治疗决策时需权衡获益与远期风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Testicular cancer (TC) treatment increases risk of subsequent malignant neoplasms (SMNs). It is unknown whether changes in TC treatment over time have affected SMN risk. Methods Solid SMN risk was evaluated in a multicenter cohort comprising 5,848 1-year survivors treated for TC before age 50 years between 1976 and 2007. SMN incidence was compared with cancer incidence in the general population. Treatment-specific risks were assessed using multivariable regression in a case-cohort design. Results After a median follow-up of 14.1 years, 350 solid SMNs were observed, translating into a 1.8-fold (95% CI, 1.6-2.0) increased risk compared with general population rates. Solid SMN risk was increased in patients with seminoma and those with nonseminoma (standardized incidence ratio, 1.52 and 2.21, respectively). Patients with nonseminoma experienced increased risk of SMNs of the thyroid, lung, stomach, pancreas, colon, and bladder and of melanoma and soft tissue sarcoma, whereas those with seminoma experienced increased risk of SMNs of the small intestine, pancreas, and urinary bladder. The 25-year cumulative incidence of solid SMNs was 10.3% (95% CI, 9.0% to 11.6%). In multivariable analysis, platinum-based chemotherapy was associated with increased risk of a solid SMN (hazard ratio [HR], 2.40; 95% CI, 1.58 to 3.62), colorectal SMN (HR, 3.85; 95% CI, 1.67 to 8.92), and noncolorectal GI SMN (HR, 5.00; 95% CI, 2.28 to 10.95). Receipt of platinum 400 to 499 and ≥ 500 mg/m2 increased solid SMN risk compared with surgery only (HR, 2.43; 95% CI, 1.40 to 4.23 and HR, 2.42; 95% CI, 1.50 to 3.90, respectively), whereas risk was not significantly increased with lower doses (HR, 1.75; 95% CI, 0.90 to 3.43). The HR of a GI SMN increased by 53% (95% CI, 26% to 80%) per 100 mg/m2 of platinum-containing chemotherapy. The HR of an infradiaphragmatic SMN increased by 8% per Gray of radiation dose administered (95% CI, 6% to 9%; P < .001). Conclusion Radiotherapy and platinum-containing chemotherapy are associated with increased solid SMN risk, specifically with GI SMNs.
引用
- Groot HJ, Lubberts S, de Wit R, et al. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol. 2018. PMID: 29989856. doi:10.1200/JCO.2017.77.4174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。